Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
Summary
None With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, including those for pneumoniae and typhoid. "Jaeyong Ahn, CEO and President of SK bioscience, said, "We are delighted to continue developing partnerships with global firms that have next-generation vaccine technology. Through our mid- to long-term collaboration with FinaBio, we will advance the vaccines we are developing to the next level and strengthen our competitiveness for global market expansion. In July 2024, SK bioscience inked a Simple Agreement for Future Equity (SAFE) with Sunflower Therapeutics, a U.S. biotech company known for its own yeast-based protein manufacturing technology, which facilitates the development and production of diverse antigens and antibodies.SK bioscience continues to secure its competitiveness through strategic investments in promising companies with exceptional technology and M&As to lay the foundation for a great leap forward into a leading global company.SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe.